TACE plus oral drugs vs. immunotherapy for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares two treatments for liver cancer that cannot be removed by surgery: TACE (a procedure that blocks the tumor's blood supply) plus an oral drug cocktail versus TACE plus standard immunotherapy. The goal is to see which approach works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of hepatocellular carcinoma (a type of liver cancer) that cannot be cured with surgery, ablation, or transplant.
- You must not have had any previous treatment for your liver cancer, including embolization procedures or cancer drugs.
- Your liver function must be good enough (Child-Pugh class A or B 7).
- You must not have another active cancer (except for certain low-risk or cured early cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This Phase 3 trial tests whether combining camrelizumab and apatinib with TACE before/around liver cancer surgery can improve outcomes for people with certain stages of hepatocellular carcinoma (HCC). It may help by strengthening the immune attack on cancer and by blocking blood supply to tumors.
This trial tests whether combining TACE (a procedure that blocks blood supply to the tumor) with three medicines (SHR-8068, adebrelimab, and bevacizumab) works better than TACE alone for people with incurable liver cancer that can't be removed surgically.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial tests a combination of liver-directed therapy (TACE) with two drugs—bevacizumab (Avastin) and atezolizumab (Tecentriq)—as a first treatment for liver cancer that cannot be removed by surgery. The goal is to see if this approach helps shrink tumors and control the disease longer.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.